We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
Read MoreHide Full Article
Thermo Fisher Scientific Inc.'s (TMO - Free Report) first-quarter 2022 adjusted earnings per share (EPS) of $7.25 beat the Zacks Consensus Estimate by 17.5%. The figure edged up 0.6% year over year.
The adjusted number excludes certain non-recurring expenses, including asset amortization costs and certain restructuring costs.
GAAP EPS was $5.61, reflecting a 4.6% rise on a year-over-year basis.
Revenues in Detail
Revenues in the quarter under review grossed $11.82 billion, up 19% year over year. The top line exceeded the Zacks Consensus Estimate by 11.2%.
Segment Details
Organic revenues in the reported quarter rose 3% year over year, while currency translation lowered revenues by 2%. Acquisitions contributed 18% to the top line and core organic revenue growth (considering the impact of PPD revenue, excluding the impacts of COVID-19 testing revenue, and excluding the impacts of acquisitions other than PPD and currency translation) was 16%.
Thermo Fisher operates under four business segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Revenues at the Life Sciences Solutions segment (35.8% of total revenues) rose 0.7% year over year to $4.23 billion while Analytical Instruments Segment sales (12.8%) improved 9.4% to $1.52 billion.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Revenues at the Laboratory Products and Biopharma Services segment (46%) rose 51.3% to $5.44 billion. The Specialty Diagnostics segment (12.5%) however recorded an 8.2% year-over-year fall in revenues to $1.48 billion.
Margin Analysis
Gross margin of 47.4% in the first quarter contracted 657 basis points (bps) year over year on a 36.4% rise in the cost of revenues.
In the quarter, selling, general and administrative expenses increased 17.2% to $1.81 billion. Research and development expenses were $364 million, up 13.8% year over year.
The adjusted operating margin for the quarter came in at 28.9%, reflecting a contraction of 613 bps.
Financial Position
The company exited the first quarter of 2022 with cash and cash equivalents of $2.75 billion compared with $4.48 billion at the end of 2021.
Cumulative net cash provided by operating activities was $2.20 billion compared with $1.98 billion a year ago.
Meanwhile, Thermo Fisher has a consistent dividend-paying history,with the five-year annualized dividend growth being 14.9%.
Guidance
The company stated that it will come up with its updated 2022 financial guidance on its earnings conference call.
Our Take
Thermo Fisher exited the first quarter with better-than-expected results. The robust year-over-year revenue growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising. The revenue contributions from the company’s acquisitions also instill optimism.
However, the year-over-year decline in revenues in the Specialty Diagnostics segment is disappointing. The contraction of both margins does not bode well either.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Here are a few stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Qiagen N.V. (QGEN - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Centene Corporation (CNC - Free Report) .
Qiagen, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 80 cents, which beat the Zacks Consensus Estimate by 12.7%. Revenues of $628.4 million outpaced the consensus mark by 6.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Qiagen has an estimated long-term growth rate of 11.5%. QGEN’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.7%.
UnitedHealth, having a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Centene reported first-quarter 2022 adjusted EPS of $1.83, which surpassed the Zacks Consensus Estimate by 8.9%. First-quarter revenues of $37.2 billion outpaced the Zacks Consensus Estimate by 7.2%. It currently has a Zacks Rank #2.
Centene has an estimated long-term growth rate of 14.2%. CNC has an earnings yield of 6.6% compared with the industry’s 5.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
Thermo Fisher Scientific Inc.'s (TMO - Free Report) first-quarter 2022 adjusted earnings per share (EPS) of $7.25 beat the Zacks Consensus Estimate by 17.5%. The figure edged up 0.6% year over year.
The adjusted number excludes certain non-recurring expenses, including asset amortization costs and certain restructuring costs.
GAAP EPS was $5.61, reflecting a 4.6% rise on a year-over-year basis.
Revenues in Detail
Revenues in the quarter under review grossed $11.82 billion, up 19% year over year. The top line exceeded the Zacks Consensus Estimate by 11.2%.
Segment Details
Organic revenues in the reported quarter rose 3% year over year, while currency translation lowered revenues by 2%. Acquisitions contributed 18% to the top line and core organic revenue growth (considering the impact of PPD revenue, excluding the impacts of COVID-19 testing revenue, and excluding the impacts of acquisitions other than PPD and currency translation) was 16%.
Thermo Fisher operates under four business segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Revenues at the Life Sciences Solutions segment (35.8% of total revenues) rose 0.7% year over year to $4.23 billion while Analytical Instruments Segment sales (12.8%) improved 9.4% to $1.52 billion.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Thermo Fisher Scientific Inc. price-consensus-eps-surprise-chart | Thermo Fisher Scientific Inc. Quote
Revenues at the Laboratory Products and Biopharma Services segment (46%) rose 51.3% to $5.44 billion. The Specialty Diagnostics segment (12.5%) however recorded an 8.2% year-over-year fall in revenues to $1.48 billion.
Margin Analysis
Gross margin of 47.4% in the first quarter contracted 657 basis points (bps) year over year on a 36.4% rise in the cost of revenues.
In the quarter, selling, general and administrative expenses increased 17.2% to $1.81 billion. Research and development expenses were $364 million, up 13.8% year over year.
The adjusted operating margin for the quarter came in at 28.9%, reflecting a contraction of 613 bps.
Financial Position
The company exited the first quarter of 2022 with cash and cash equivalents of $2.75 billion compared with $4.48 billion at the end of 2021.
Cumulative net cash provided by operating activities was $2.20 billion compared with $1.98 billion a year ago.
Meanwhile, Thermo Fisher has a consistent dividend-paying history,with the five-year annualized dividend growth being 14.9%.
Guidance
The company stated that it will come up with its updated 2022 financial guidance on its earnings conference call.
Our Take
Thermo Fisher exited the first quarter with better-than-expected results. The robust year-over-year revenue growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising. The revenue contributions from the company’s acquisitions also instill optimism.
However, the year-over-year decline in revenues in the Specialty Diagnostics segment is disappointing. The contraction of both margins does not bode well either.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Here are a few stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Qiagen N.V. (QGEN - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Centene Corporation (CNC - Free Report) .
Qiagen, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 80 cents, which beat the Zacks Consensus Estimate by 12.7%. Revenues of $628.4 million outpaced the consensus mark by 6.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Qiagen has an estimated long-term growth rate of 11.5%. QGEN’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.7%.
UnitedHealth, having a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Centene reported first-quarter 2022 adjusted EPS of $1.83, which surpassed the Zacks Consensus Estimate by 8.9%. First-quarter revenues of $37.2 billion outpaced the Zacks Consensus Estimate by 7.2%. It currently has a Zacks Rank #2.
Centene has an estimated long-term growth rate of 14.2%. CNC has an earnings yield of 6.6% compared with the industry’s 5.6%.